NEW YORK (GenomeWeb) – Enigma Diagnostics and Beijing Leadman Biochemistry today announced a joint venture agreement aimed at bringing Enigma's point-of-care molecular diagnostic system to China.
Engima also announced a $50 million subscription agreement with a Chinese private equity fund.